Active surveillance for intermediate-risk prostate cancer
Authors:
- 19 January 2022
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 40 (1) , 79-86
Abstract
Introduction Active surveillance (AS) is an established approach in the management of low-risk, localized prostate cancer. While the use of AS to manage intermediate-risk (IR) disease has gradually increased over time, there remains uncertainty with regards to its safety, with only a minority of IR patients currently being managed with this approach. Materials and Methods We conducted a narrative review based on an analysis of the literature focusing on articles describing AS for IR prostate cancer. We focus on the uncertainty surrounding AS in IR disease by discussing variations in the definitions and guideline recommendations associated with IR disease, and describing the limitations of the evidence from observational studies and randomized trials. Conclusion The safety of AS for IR disease remains unknown, given the lack of randomized trials and the limitations of the current observational studies. Further research is needed to identify select patients with IR prostate cancer that can be managed safely with AS.Keywords
This publication has 45 references indexed in Scilit:
- Radical Prostatectomy or Watchful Waiting in Early Prostate CancerNew England Journal of Medicine, 2014
- Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS StudyEuropean Urology, 2013
- Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2013
- Outcomes of initially expectantly managed patients with low or intermediate risk screen‐detected localized prostate cancerBJU International, 2012
- Radical Prostatectomy versus Observation for Localized Prostate CancerNew England Journal of Medicine, 2012
- Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?The Lancet Oncology, 2012
- Outcomes of Active Surveillance for Men With Intermediate-Risk Prostate CancerJournal of Clinical Oncology, 2011
- Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and BiorepositoryUrology, 2010
- Risk Assessment for Prostate Cancer Metastasis and Mortality at the Time of DiagnosisJNCI: Journal of the National Cancer Institute, 2009
- Automated variable selection methods for logistic regression produced unstable models for predicting acute myocardial infarction mortalityJournal of Clinical Epidemiology, 2004